27 NOVEMBER 2026

ASX RELEASE

APPENDIX 4D AND FINANCIAL REPORT HALF YEAR ENDED 30 SEPTEMBER 2026

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX; OTCQB: INNMF), referred to as "Amplia" or "the Company," announces its Appendix 4D and Financial Report for the Half Year ended 30 September 2026.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:
Hannah Howlett, Titch Comms
Hannah@titchcomms.com.au
+61 450 648 064

U.S. Contact:
Robert Giordano
rjgiordano@ggrouplifesciences.com
+1 917 327 3938

U.S. Media:
media@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit **www.ampliatx.com** and follow Amplia on X (@ampliatx) and **LinkedIn**.

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has achieved its desired outcome in achieving a confirmed response rate of 36%, superior to chemotherapy alone, and a mOS of 11.1 months has been reported. Additional clinical studies in lung and ovarian cancer are in late-stage planning with further information available on the Company's website **www.ampliatx.com**.

Amplia Therapeutics Limited
Appendix 4D
Half-year report

1. Company details

Name of entity:	Amplia Therapeutics Limited
ACN:	165 160 841
Reporting period:	For the half-year ended 30 September 2026
Previous period:	For the half-year ended 30 September 2025

2. Results for announcement to the market

				$
Revenues from ordinary activities and other income	up	4%	to	2,939,126
Loss from ordinary activities after tax attributable to the owners of Amplia Therapeutics Limited	up	11%	to	(4,625,320)
Loss for the half-year attributable to the owners of Amplia Therapeutics Limited	up	11%	to	(4,625,320)

Dividends
The Directors have resolved that no dividend will be paid this half year.

Comments
The loss for the Group after providing for income tax for the half-year ended 30 September 2026 amounted to $4,625,320 (30 September 2025: $4,176,563).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	5.2	6.8

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period
There were no dividends paid, recommended or declared during the current financial period.

Previous period
There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Half Year Report.

11. Attachments

Details of attachments (if any):

The Half Year Report of Amplia Therapeutics Limited for the half-year ended 30 September 2026 is attached.

12. Signed

Signed  Date: 27 November 2026

Jane Bell
Non-Executive Chair

Amplia Therapeutics Limited

ACN 165 160 841

Half Year Report - 30 September 2026

Amplia Therapeutics Limited
Corporate directory
30 September 2026

Directors	Ms Jane Bell AM (Non-Executive Chair) - Appointed Chair 30 June 2026 Dr Robert Peach (Non-Executive Director) Dr Christopher Burns (CEO and Managing Director) Dr Warwick Tong (Non-Executive Director) - Resigned as Chair 30 June 2026 Mr Brett Carter (Non-Executive Director) - Appointed 6 July 2026
Company secretary	Mr Andrew J. Cooke
Registered office	Level 5, 90 William Street Melbourne VIC 3000 Australia
Share register	Computershare Investor Services Pty Limited Level 3, 60 Carrington Street Sydney NSW 2000 Australia Telephone: 1300 556 161 (within Australia) + 61 3 9415 4000 (outside Australia) Website: www.investorcentre.com/contact
Auditor	Grant Thornton Audit Pty Ltd Australia
Stock exchange listing	Amplia Therapeutics Limited shares are listed on the Australian Securities Exchange (ASX code: ATX)
Website	www.ampliatx.com

Amplia Therapeutics Limited
Contents
30 September 2026

Directors' report	3
Auditor's independence declaration	8
Consolidated statement of profit or loss and other comprehensive income	9
Consolidated statement of financial position	10
Consolidated statement of changes in equity	11
Consolidated statement of cash flows	12
Notes to the consolidated financial statements	13
Directors' declaration	20
Independent auditor's review report to the members of Amplia Therapeutics Limited	21

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Amplia Therapeutics Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 30 September 2026.

Directors

The names of the Directors in office at any time during or since the period are:

Name and independence status	Period of office and special responsibilities
Jane Bell Independent Non-Executive Chair	Appointed as Non-Executive Director on 12 April 2021 and Chair on 30 June 2026. Was Chair of Audit and Risk Committee up to 15 July 2026 and is a member of the Remuneration and Nomination Committee.
Robert Peach Independent Non-Executive Director	Appointed as Non-Executive Director on 2 September 2015 and is Chair of the Remuneration and Nomination Committee and a member of the Audit & Risk Committee.
Warwick Tong Independent Non-Executive Director	Appointed as Non-Executive Director on 4 May 2018 and Chair from 25 May 2018 to 30 June 2026. Member of the Audit & Risk Committee and the Remuneration and Nomination Committee.
Christopher Burns CEO and Managing Director	Appointed as Non-Executive Director on 4 May 2018. Appointed Chief Executive Officer and Managing Director starting 5 December 2022.
Brett Carter Independent Non-Executive Director	Appointed as Non-Executive Director on 6 July 2026 and Chair of Audit and Risk Committee from 16 July 2026.

Principal activities

The principal activity of the Company is development of its Focal Adhesion Kinase (FAK) inhibiting drug candidates Narmafotinib (AMP945) and AMP886. These assets represent highly attractive compounds for clinical development possessing excellent potency and selectivity in biological assay systems; good pharmacokinetics, bioavailability and drug-like properties; promising efficacy in a range of preclinical studies; and, appropriate chemical properties for manufacturing scale-up and long-term stability. The Company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases.

Financial update

The loss for the Group after providing for income tax for the half-year period ended 30 September 2026 amounted to $4,625,320 (30 September 2025: $4,176,563).

Total current assets at the beginning of the period amounted to $33,042,051 which cash and cash equivalents totalled $27,854,032. At 30 September 2026, total current assets had decreased to $28,561,635. Of this amount, $20,772,644 was represented by cash and cash equivalents and $7,307,282 was represented by the R&D tax incentive receivable.

Total liabilities at the beginning of the period amounted to $2,405,658. This decreased to $2,106,200 by 30 September 2026.

Review of operations

The focus for the Company over the reporting period has been on building on the mature clinical data from the ACCENT trial of our lead asset narmafotinib in pancreatic cancer, and on advancing narmafotinib towards a registrational study in this indication. Over the half year the Company also broadened the clinical development of narmafotinib beyond pancreatic cancer, with new studies in planning in ovarian cancer and non-small cell lung cancer (NSCLC).

In April 2026, mature data from the ACCENT trial, which is investigating narmafotinib in combination with the chemotherapies gemcitabine and Abraxane®, was selected for oral presentation at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, USA. Independent central reading of the data identified five confirmed complete responses from 64 patients, a complete response rate of 7.8% compared to 0.2% for chemotherapy alone. The objective response rate (ORR) was 36% (42% when unconfirmed responses are included), and the disease control rate was 70% compared to 50% for chemotherapy alone. The ORR is a globally acknowledged metric of clinical efficacy in oncology trials and represents the percentage of patients who achieve a clinical response (complete or partial) that is sustained for >2 months. Median overall survival was 11.1 months and median progression-free survival was 7.7 months, both improvements of more than two months compared to chemotherapy alone.

Importantly, narmafotinib showed a manageable toxicity profile, with no significant tolerability burden over chemotherapy alone. These results were achieved with an intermittent dosing schedule (12 days of each 28-day treatment cycle). Given the tolerability seen to date, daily dosing of narmafotinib will be explored in a new study called ACCENT- Mini, as a more patient-convenient and potentially more efficacious treatment regimen. This new study forms the first stage of a registration-enabling trial of narmafotinib in pancreatic cancer, designed in line with US Food and Drug Administration (FDA) feedback. It will investigate daily dosing of narmafotinib at 2-3 dose levels in combination with gemcitabine and Abraxane in newly diagnosed patients, with safety, tolerability, pharmacokinetics (PK) and efficacy as key endpoints. Patient enrolment is planned to begin in Q4 2026 and the key safety, tolerability and PK data will be available around end Q1 2027.

In August 2026, the Company signed a Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company (Lilly) to evaluate narmafotinib in combination with olomorasib, Lilly's investigational next-generation KRAS G12C inhibitor. The Phase 1b/2b trial will assess the safety and efficacy of the combination as a second-line treatment for patients with advanced NSCLC. Amplia will conduct the study, with Lilly supplying olomorasib. The study is planned to begin in late 2026 at sites in Australia and the USA. The collaboration is supported by a strong scientific rationale that FAK activation is a key driver of resistance to KRAS G12C inhibitors, and it extends narmafotinib's clinical development into a major new indication. This study also provides Amplia the opportunity to demonstrate that narmafotinib may enhance the efficacy of kRAS inhibitors, and area of considerable commercial and clinical interest.

The Company also announced that it had entered into an agreement with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to conduct the PRROSE trial. This investigator-initiated study will evaluate narmafotinib in combination with standard-of-care chemotherapy (carboplatin and paclitaxel) in patients with high-grade serous ovarian cancer who respond poorly to chemotherapy before planned debulking surgery. The study is led by Dr Gwo Yaw Ho of Monash Health and Monash University and is sponsored and coordinated by ANZGOG. In September the Company and ANZGOG announced that the trial protocol had been finalised. Approximately 26 patients are expected to be enrolled at sites in Australia and New Zealand, and site activation and ethics approval are planned before the end of 2026.

During the reporting period the Company halted recruitment into the AMPLICITY trial, which was investigating narmafotinib in combination with the chemotherapy regimen modified FOLFIRINOX. Three dose-limiting toxicities were observed, none of which were attributed to narmafotinib, but related to the chemotherapy regimen. Patients already on the trial continued treatment, and the Company redirected resources to the ACCENT-Mini and Lilly combination studies.

In July 2026, a scientific manuscript describing extensive preclinical studies of narmafotinib in pancreatic cancer was published on the preprint server bioRxiv. The research was conducted at the Garvan Institute of Medical Research, Sydney. Key findings presented in the manuscript show that narmafotinib treatment, in preclinical pancreatic cancer models:
- reduced tumour fibrosis
- enhanced anti-tumour activity when narmafotinib was combined with chemotherapy
- reduced cancer spread and metastasis
- reduced activity of multiple genes linked to chemotherapy resistance

These findings further strengthen the scientific rationale for the clinical development of narmafotinib.

Also in July, the Company announced the publication of a new patent application describing chemically novel FAK inhibitors discovered by Amplia. If granted, it would protect the new molecules and their use until 2046. This further strengthens the Company's FAK inhibitor intellectual property portfolio and creates future development and partnering options.

The Company implemented its Board succession plans during the period. Ms Jane Bell AM was appointed Chair effective 30 June 2026, following Dr Warwick Tong's retirement as Chair; Dr Tong continues as a Non-Executive Director. Mr Brett Carter, an experienced biopharmaceutical executive, was appointed as a Non-Executive Director in July 2026. The Company's Annual General Meeting was held on 28 August 2026.

Material Business Risks

The current and future performance of the Group may be affected by changing circumstances, uncertainties, and risks specific to the Group and the Group’s business activities, as well as general risks.

(a) Clinical development risk

The nature of clinical drug development has inherent risks, with many drug candidates entering clinical trial failing to be successfully developed into marketable products. The Group is currently undertaking a clinical trial with its lead drug narmafotinib in advanced pancreatic cancer patients. Clinical trials have many associated risks which may impact commercial potential and therefore future profitability. Such trials may fail to recruit patients at a sufficient rate, and a slower than expected recruitment will mean slower than expected data points so a longer period incurring overheads and personnel costs. Clinical trialling may reveal drug candidates to be unsafe or poorly tolerated in the patient population being tested. The drugs may also be shown to be only modestly effective, thereby limiting commercial potential, or ineffective. Any of these outcomes will likely have a significant adverse effect on the Group, the value of its securities and the future commercial development of its drug candidates, including narmafotinib. Clinical trials might also potentially expose the Group to product liability claims in the event its products in development have unexpected effects on clinical subjects.

(b) Regulatory approvals necessary for clinical trials

The Group may be unable to secure and maintain necessary approvals from regulatory agencies and institutional bodies (clinics and hospitals) to conduct its clinical trials. Using funds raised in the Offer, the Group plans to initiate a Phase 2 clinical trial (as an Investigator Initiated Trial) in advanced ovarian cancer patients. There is no assurance that regulatory bodies and local ethics committees will approve the Group's plans to recruit these patients.

(c) Regulatory and reimbursement approvals

The research, development, manufacture, marketing and sale of products developed by the Group are subject to varying degrees of regulation by a number of government authorities in Australia and overseas. Pharmaceutical products under development, such as drug candidate narmafotinib, must undergo a comprehensive and highly regulated development and review process before receiving approval for marketing. The process includes the provision of clinical data relating to the quality, safety and efficacy of the products for their proposed use. There is no guarantee that such regulatory approvals will be granted.

(d) Chemistry, manufacturing and controls

The ACCENT clinical trial currently underway requires supply of narmafotinib drug product (capsules). There are risks in the shipment, storage and handling of drug product that may render the material unavailable or inappropriate for clinical usage. For clinical trial sites in South Korea, supplies of the chemotherapies gemcitabine and Abraxane are also required. There are risks in the supply, shipment, storage and handling of drug product that may render the material unavailable or inappropriate for clinical usage.

(e) Commercialisation of products and potential market failure

The Group has not yet commercialised any products and as yet has no revenues. The Group is also dependent on commercially attractive markets remaining available to it during the commercialisation phase and there is a risk that, once developed and ready for sale, commercial sales may not be achieved.

Furthermore, any products developed by the Group may prove to be uneconomical to market or compete with alternative products marketed by third parties, or not be as attractive or efficacious as alternative treatments.

(f) Competition

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant change. A number of companies, both in Australia and abroad, may be pursuing the development of products that target the same markets and/or diseases that the Group is targeting.

The Group's products may compete with existing products that are already available to customers. The Group may face competition from parties who have substantially greater resources than the Group. Competing products may be superior to the Group's products, which would adversely impact the commercial viability of the Group's products.

(g) Dependence upon key personnel

The Group’s ability to attract and retain personnel will have a direct impact on its ability to deliver its project commitments. The Group depends on the talent and experience of its personnel as an important asset. There may be a negative impact on the Group if any of its key personnel leave. It may be difficult to replace them, or to do so in a timely manner or at comparable expense. Additionally, any key personnel of the Group who leave to work for a competitor may adversely impact the Group.

Additionally, increases in recruitment fees, wages and contractor costs may adversely impact upon the financial performance of the Group.

(h) Research & Development (R&D) Tax Incentive Rebates

The Group is currently entitled to receive an R&D rebate on part of its expenditure in research and development. There is a risk that the Australian Government may make material changes to the rebate scheme, which may adversely impact the funding available to the Group to fund its operations.

In order to obtain an R&D rebate on that part of its expenditure that is incurred out of Australia the Group must first gain approval for that expenditure from the Australian Government. Such an approval is called an Advanced Finding. The Group has received Advanced Findings for R&D work which is planned for its lead assets narmafotinib and AMP886.

(i) Commercial partners

The Group's growth strategy may be impacted if it is unable to find suitable commercialisation partners. The Group's due diligence processes may not be successful and a commercial partnership may not perform to the level expected.

(j) Intellectual Property

The Group's ability to commercialise any product depends upon its ability to protect its intellectual property and any improvements to it. The intellectual property may not be capable of being legally protected, it may be the subject of unauthorised disclosure or be unlawfully infringed, or the Group may incur substantial costs in asserting or defending its intellectual property rights.

(k) Revenues and Profitability

The Group does not currently generate revenue from product sales nor are revenues anticipated in the short to medium term. The Group's ability to achieve both revenues and profitability is dependent on a number of factors, including its ability to complete successful clinical trials, obtain regulatory approval for its products and successfully commercialise those products. There is no guarantee that the Group's products (including the drug narmafotinib) will be commercially successful.

(l) Economic

General economic conditions, movements in financial markets, interest and inflation rates and currency exchange rates may have an adverse effect on the Group's business and production activities, as well as on its ability to fund those activities.

(m) Market Conditions

Share market conditions may affect the value of the Group's quoted shares (and options to acquire quoted shares) regardless of the Group's operating performance. Share market conditions are affected by many factors such as:

(a) general economic outlook;
(b) introduction of tax reform or other new legislation;
(c) interest rates and inflation rates;
(d) changes in investor sentiment toward particular market sectors;
(e) the demand for, and supply of, capital; and
(f) terrorism or other hostilities.

The market price of securities can fall as well as rise and may be subject to varied and unpredictable influences on the market for equities in general and pharmaceutical stocks in particular. Neither the Group nor the Directors warrant the future performance of the Group or any return on an investment in the Group.

(n) Litigation

There is a risk that the Group may in future be the subject of or required to commence litigation. There is, however, no litigation, mediation, conciliation or administrative proceeding taking place, pending or threatened against the Group.

(o) Tax risks

Changes to the rate of taxes imposed on the Group (including in overseas jurisdictions in which the Group operates now or in the future) or tax legislation generally may affect the Group and its shareholders. In addition, an interpretation of Australian tax laws by the Australian Taxation Office that differs to the Group's interpretation may lead to an increase in the Group's tax liabilities and a reduction in shareholder returns. Personal tax liabilities are the responsibility of each individual investor. The Group is not responsible either for tax or tax penalties incurred by investors.

(p) Additional capital requirements

The Group's capital requirements depend on numerous factors. The Group may require further financing in addition to amounts raised under the capital raising. Any additional equity financing will dilute shareholdings, and debt financing, if available, may involve restrictions on financing and operating activities. If the Group is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations, its production levels, or scale back its research and development and/or clinical trials as the case may be. There is no guarantee that the Group will be able to secure any additional funding or be able to secure funding on terms favourable to the Group.

Significant changes in the state of affairs

During the period, the Company experienced the following significant changes in its state of affairs:

- On 7 April 2026, the Company announced a temporary halt to recruitment in the AMPLICITY trial following protocol-defined safety events, with no concerns identified for narmafotinib.
- On 8 May 2026, the Company entered into an agreement with Australia New Zealand Gynaecological Oncology Group (ANZGOG) to conduct clinical study in ovarian cancer.
- On 12 May 2026, the Company issued 240,385 fully paid ordinary shares following the exercise of employee options.
- On 19 May 2026, The Company initiated a Phase 2b study of narmafotinib in advanced pancreatic cancer, representing the first stage of its planned registration-enabling clinical program.
- On 30 June 2026, Jane Bell was appointed as Chair and Warwick Tong stepped down from position as Chair to Non-Executive Director.
- On 6 July 2026, Brett Carter was appointed as Non-Executive Director.
- On 16 July 2026, Brett Carter was appointed as Chair of Audit and Risk Committee.
- On 4 August 2026, the Company entered into Clinical Trial Collaboration and Supply Agreement (CTCSA) with Lilly to evaluate narmafotinib with olomorasib in non-small cell lung cancer.

There were no other significant changes in the state of affairs of the Company during the financial half-year.

Matters subsequent to the end of the financial half-year

On 22 October 2026, the Company received an R&D Tax Incentive refund of $4,778,235 for the financial year ended 31 March 2026.

No other matter or circumstance has arisen since 30 September 2026 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report.

This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the Directors



Jane Bell
Non-Executive Chair

27 November 2026

Grant Thornton Audit Pty Ltd
Level 22 Tower 5
Collins Square
727 Collins Street
Melbourne VIC 3008
GPO Box 4736
Melbourne VIC 3001
T +61 3 8320 2222

Auditor's Independence Declaration

To the Directors of Amplia Therapeutics Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of Amplia Therapeutics Limited for the half-year ended 30 September 2026. I declare that, to the best of my knowledge and belief, there have been:

a no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and

b no contraventions of any applicable code of professional conduct in relation to the review.

Grant Thornton Audit Pty Ltd
Chartered Accountants

J D Vasiliou
Partner – Audit & Assurance

Melbourne, 27 November 2026

© 2026 Grant Thornton Audit Pty Ltd. as trustee for the Grant Thornton Audit Unit Trust

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Audit Pty Ltd as trustee for the Grant Thornton Audit Unit Trust is a member firm of Grant Thornton International Ltd (GTIL) and is part of the Grant Thornton Advisors (GTA) multinational platform (being a group of firms within the GTIL network that connects priority markets and operates with aligned standards, technology and delivery expectations). GTIL, GTIL member firms, and the GTA platform firms are separate legal entities, are not a worldwide partnership, are not agents of and do not obligate one another, and are not liable for one another's acts or omissions. Services are delivered by the member firms; GTIL does not provide services to clients. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Audit Pty Ltd as trustee for the Grant Thornton Audit Unit Trust and its related entities. Liability limited by a scheme approved under Professional Standards Legislation.

Amplia Therapeutics Limited
Consolidated statement of profit or loss and other comprehensive income
For the half-year ended 30 September 2026

	Note	30 September 2026 $	30 September 2025 $
Revenue and other income			
R&D tax incentive	6	2,529,047	2,630,572
Interest income		410,079	204,525
Total revenue and other income		2,939,126	2,835,097
Expenses			
Research & development expenses		(4,913,502)	(4,999,152)
Administrative & general expenses		(2,005,826)	(1,759,950)
Share based compensation		(399,809)	(53,575)
Patent & associated expenses		(168,436)	(158,082)
Depreciation and amortisation expense		(65,601)	(36,297)
Total expenses		(7,553,174)	(7,007,056)
Operating loss		(4,614,048)	(4,171,959)
Interest expense		(11,272)	(4,604)
Loss before income tax expense		(4,625,320)	(4,176,563)
Income tax expense		-	-
Loss after income tax expense for the half-year attributable to the owners of Amplia Therapeutics Limited		(4,625,320)	(4,176,563)
Other comprehensive income for the half-year, net of tax		-	-
Total comprehensive loss for the half-year attributable to the owners of Amplia Therapeutics Limited		(4,625,320)	(4,176,563)
		Cents	**Cents**
Basic and diluted earnings per share	12	(0.90)	(0.98)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Amplia Therapeutics Limited
Consolidated statement of financial position
As at 30 September 2026

	Note	30 September 2026 $	31 March 2026 restated* $
Assets			
Current assets			
Cash and cash equivalents		20,772,644	27,854,032
R&D tax incentive receivable	7	7,307,282	4,778,235
Prepayments		284,334	170,154
Other assets		197,375	239,630
Total current assets		28,561,635	33,042,051
Non-current assets			
Property, plant and equipment		87,025	24,429
Right-of-use assets		280,097	329,525
Intangibles	8	7,937,932	7,937,932
Other assets		49,271	106,992
Total non-current assets		8,354,325	8,398,878
Total assets		36,915,960	41,440,929
Liabilities			
Current liabilities			
Accounts payable & accrued liabilities		1,647,002	1,924,053
Lease liabilities		94,582	89,251
Provisions		98,749	94,112
Total current liabilities		1,840,333	2,107,416
Non-current liabilities			
Lease liabilities		203,378	251,860
Provisions		62,489	46,382
Total non-current liabilities		265,867	298,242
Total liabilities		2,106,200	2,405,658
Net assets		34,809,760	39,035,271
Equity			
Issued capital	9	193,461,727	193,430,477
Reserves	10	(759,891)	(1,128,450)
Accumulated losses		(157,892,076)	(153,266,756)
Total equity		34,809,760	39,035,271

* Refer to Note 4 for details of the restatement of prior period balance.

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

Amplia Therapeutics Limited
Consolidated statement of changes in equity
For the half-year ended 30 September 2026

	Issued capital $	Share option reserve $	Other reserves $	Accumulated losses $	Total equity $
Balance at 1 April 2025	167,389,241	992,424	(1,818,617)	(145,538,098)	21,024,950
Adjustment for correction of error (note 4)	-	-	-	(437,000)	(437,000)
Balance at 1 April 2025 - restated	167,389,241	992,424	(1,818,617)	(145,975,098)	20,587,950
Loss after income tax expense for the half-year	-	-	-	(4,176,563)	(4,176,563)
Other comprehensive income for the half-year, net of tax	-	-	-	-	-
Total comprehensive loss for the half-year	-	-	-	(4,176,563)	(4,176,563)
Transactions with owners in their capacity as owners:					
Share-based payments	-	53,575	-	-	53,575
Issue of shares	27,646,589	-	-	-	27,646,589
Issue of shares on exercise of options	253,281	(46,353)	-	31,248	238,176
Cost of issuing shares	(1,858,634)	-	-	-	(1,858,634)
Expiry of options previously recorded as share-based payments	-	(208,070)	-	208,070	-
Balance at 30 September 2025 - restated	193,430,477	791,576	(1,818,617)	(149,912,343)	42,491,093

	Issued capital $	Share option reserve $	Other reserves $	Accumulated losses $	Total equity $
Balance at 1 April 2026	193,430,477	690,167	(1,818,617)	(152,829,756)	39,472,271
Adjustment for correction of error (note 4)	-	-	-	(437,000)	(437,000)
Balance at 1 April 2026 - restated	193,430,477	690,167	(1,818,617)	(153,266,756)	39,035,271
Loss after income tax expense for the half-year	-	-	-	(4,625,320)	(4,625,320)
Other comprehensive income for the half-year, net of tax	-	-	-	-	-
Total comprehensive loss for the half-year	-	-	-	(4,625,320)	(4,625,320)
Transactions with owners in their capacity as owners:					
Share-based payments (note 10)	-	399,809	-	-	399,809
Issue of shares (note 9)	-	-	-	-	-
Issue of shares on exercise of options (note 10)	31,250	(31,250)	-	-	-
Balance at 30 September 2026	193,461,727	1,058,726	(1,818,617)	(157,892,076)	34,809,760

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Amplia Therapeutics Limited
Consolidated statement of cash flows
For the half-year ended 30 September 2026

	30 September 2026 $	30 September 2025 $
Cash flows from operating activities		
Interest received	425,013	155,867
Payments to suppliers	(6,513,666)	(6,954,789)
Payments to employees	(911,614)	(848,418)
Net cash used in operating activities	(7,000,267)	(7,647,340)
Cash flows from investing activities		
Payments for property, plant and equipment	(78,769)	(26,009)
Payment from/(for) bank guarantee	57,721	(53,958)
Net cash used in investing activities	(21,048)	(79,967)
Cash flows from financing activities		
Proceeds from issue of shares	-	27,646,589
Proceeds from issue of shares from the exercise of options	-	238,176
Capital raising costs	-	(1,809,374)
Repayment of lease liabilities	(54,422)	(31,834)
Finance costs paid	(11,272)	(4,603)
Net cash (used in)/from financing activities	(65,694)	26,038,954
Net (decrease)/increase in cash and cash equivalents	(7,087,009)	18,311,647
Cash and cash equivalents at the beginning of the financial half-year	27,854,032	10,863,278
Effects of exchange rate changes on cash and cash equivalents	5,621	(18,464)
Cash and cash equivalents at the end of the financial half-year	20,772,644	29,156,461

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Note 1. General information

The financial statements cover Amplia Therapeutics Limited as a Group consisting of Amplia Therapeutics Limited and the entity it controlled at the end of, or during, the half-year (together referred to as the "Group" and individually as "Group entities"). The financial statements are presented in Australian dollars, which is Amplia Therapeutics Limited's functional and presentation currency.

A description of the nature of the Group's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of Directors, on 27 November 2026.

Note 2. Reporting entity

Amplia Therapeutics Limited (the 'Company') is a company domiciled in Australia. The condensed consolidated interim financial statements of the Company as at and for the six months ended 30 September 2026 comprise the Company and its subsidiary.

Note 3. Material accounting policy information

These general purpose financial statements for the interim half-year reporting period ended 30 September 2026 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 31 March 2026 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period, which had no impact on the Group's financial statements.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Going concern

The financial statements have been prepared on a going concern basis, which assumes the continuity of normal business activities and realisation of assets and settlement of liabilities in the ordinary course of business.

For the half-year period ended 30 September 2026 the Group incurred a net loss of $4,625,320 and net cash used in operating activities amounted to $7,000,267.

The going concern of the Group is dependent upon it maintaining sufficient funds for its operations and commitments. The Group has the exclusive worldwide license to develop and commercialise the drug candidates AMP945 and AMP886. The exploitation of these licenses will require future funding which gives rise to a material uncertainty regarding going concern.

The Group has a successful history of:

- Raising sufficient capital to fund the Group's operations;
- Being eligible to claim the Research and Development tax incentive from the ATO for eligible spend; and
- Accessing Research and Development tax incentive advances prior to claiming Research and Development tax incentive.

Note 3. Material accounting policy information (continued)

The Group has prepared detailed cash flow forecasts and believe that they will have sufficient cash to further research and development plans for the 12 months from signing the financial report. The directors note the following in relation to the Group's cashflow forecasts:

- The Group can scale down its operations sufficiently (and narrow the scope of its planned activities) should there be a need to do so;
- The Group may be able to claim the Research and Development tax incentive from the ATO for eligible spend; and
- The Group may be able to obtain Research and Development tax incentive advances prior to claiming Research and Development tax incentive.

The Directors continue to monitor the ongoing funding requirements of the Group and are of the opinion that the financial statements have been appropriately prepared on a going concern basis. Accordingly, the financial statements do not include any adjustments relating to the recoverability or classification of recorded asset amounts or classification of liabilities that might be necessary should the Group not be able to continue as a going concern.

Note 4. Restatement of comparatives

Correction of error
During the half-year ended 30 September 2026, the Group identified that a milestone payment of $437,000 under its Research & Licence Agreement with The Garvan Institute of Medical Research had not been recognised when it became payable.

The milestone was triggered when the Group received the US Food and Drug Administration Fast Track Designation for narmafotinib, which was announced to the ASX on 20 September 2024. The obligation should therefore have been recognised as an accrued expense in the financial year ended 31 March 2025.

In accordance with AASB 108 *Accounting Policies, Changes in Accounting Estimates and Errors*, the error has been corrected retrospectively by restating each affected financial statement line item for the prior periods, as set out below.

The correction has no impact on the statement of profit or loss and other comprehensive income, the statement of cash flows or earnings per share for the half-year ended 30 September 2025

	As Previously Reported $	Adjustment $	Restated $
Statement of Financial Position - 31 March 2026 (extract)			
Accounts payable and accrued liabilities	1,487,053	437,000	1,924,053
Total current liabilities	1,670,416	437,000	2,107,416
Total liabilities	1,968,658	437,000	2,405,658
Net assets	39,472,271	(437,000)	39,035,271
Accumulated losses	(152,829,756)	(437,000)	(153,266,756)
Total equity	39,472,271	(437,000)	39,035,271
Statement of Changes in Equity – 1 April 2025 (extract)			
Accumulated losses	(145,538,098)	(437,000)	(145,975,098)
Total equity	21,024,950	(437,000)	20,587,950

Note 5. Operating segments

A segment is a component of the Group entity that earns revenues or incurs expenses whose results are regularly reviewed by the chief operating decision makers and for which discrete financial information is prepared. The Group as a whole is considered to be one operating/reportable segment, management review financial information on a consolidated basis. It has established entities in more than one geographical area, however the activities from these entities comparative to the Group are considered immaterial for the purposes of segment reporting.

Note 6. R&D tax incentive

	30 September 2026 $	30 September 2025 $
R&D tax incentive - half-year end	2,529,047	2,630,572

Note 7. R&D tax incentive receivable

	30 September 2026 $	31 March 2026 $
Current assets		
R&D tax incentive receivable - year ended 31 March 2026	4,778,235	4,778,235
R&D tax incentive receivable - half-year ended 30 September 2026	2,529,047	-
	7,307,282	4,778,235

Note 8. Intangibles

	30 September 2026 $	31 March 2026 $
Non-current assets		
Global license - AMP 945 & AMP 886 - at cost	7,937,932	7,937,932
Less: Accumulated amortisation	-	-
	7,937,932	7,937,932

Global license - AMP 945 & AMP 886 represents the cost of the separately acquired intangible assets representing the worldwide right to drug candidates AMP 945 and AMP 886, expiring in 2032.

At the reporting date, the Group's drug candidates remained in the development stage, comprising clinical and pre-clinical trials, and were not yet available for use. Accordingly, amortisation of the related intangible assets has not commenced.

Note 9. Issued capital

	30 September 2026 Shares	31 March 2026 Shares	30 September 2026 $	31 March 2026 $
Ordinary shares - fully paid	513,312,014	513,071,629	193,461,727	193,430,477

For the period ended 30 September 2026, 513,312,014 ordinary shares (31 March 2026: 513,071,629) were issued and fully paid. All ordinary shares rank equally as to voting, dividends and liquidation. There are no reserved shares of the Group. The shares have no par value.

The following movements in ordinary shares were recorded during the half-year ended.

Note 9. Issued capital (continued)

	30 September 2026 Shares	31 March 2026 Shares	30 September 2026 $	31 March 2026 $
Balance brought forward as at 1 April	513,071,629	387,952,669	193,430,477	167,389,241
Issue of shares	-	123,398,960	-	27,646,589
Issue of shares from the exercise of options	-	1,720,000	-	238,176
Issue of shares from the exercise of zero exercise price options	240,385	-	31,250	-
Transaction costs relating to issue of shares	-	-	-	(1,843,529)
Balance carried forward	513,312,014	513,071,629	193,461,727	193,430,477

Shares issued
During the half-year period to 30 September 2026, nil ordinary shares were issued and 240,385 ordinary shares were issued upon the exercise of zero exercise price options.

Options
The Company has on issue 16,845,710 shares options as at 30 September 2026. During the half-year period to 30 September 2026, 5,090,320 options were issued (including 4,102,728 zero exercise price options) and 240,385 options were exercised.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Note 10. Reserves

	30 September 2026 $	31 March 2026 $
Other reserves	(1,818,617)	(1,818,615)
Share option reserve	1,058,726	690,165
	(759,891)	(1,128,450)

Other reserves
Other reserves relate to restructuring reserves created at the time of acquisition of Amplia Therapeutics Pty Ltd.

Share option reserve
The reserve is used to recognise the value of equity benefits provided to employees and directors as part of their remuneration, and other parties as part of their compensation for services.

Share-based payments reserve
The total share-based payment expense amortised for the period ended 30 September 2026 was $399,809 (30 September 2025: $53,575). $0 was recognised in retained earnings as a reversal of share-based payment expenses relating to options that lapsed during the financial half-year that were previously recognised in profit or loss (30 September 2025: $208,070).

On the exercise of options, $31,250 was transferred to share capital.

Note 10. Reserves (continued)

Share based compensation
Options may be issued to external consultants or non-related parties without shareholders' approval, where the annual 15% capacity pursuant to ASX Listing Rule 7.1 has not been exceeded. Options cannot be offered to a director or an associate except where approval is given by shareholders at a general meeting.

Each option issued converts into one ordinary share of Amplia Therapeutics Limited on exercise. The options carry neither right to dividends nor voting rights. Options may be exercised at any time from the date of vesting to the date of their expiry.

During the period 987,592 options were granted to Consultants. The unlisted options were issued on 15 July 2026, expiring on 15 July 2028. These options vest 1/2 each year starting on grant date until the 1st anniversary of the grant date. The options have been accounted for in accordance with AASB 2 Share-based Payment as equity-settled share-based payment transactions with parties providing services similar to employees. The fair value of the options was determined at grant date using the Black-Scholes valuation model. The following table lists the inputs to the model used for valuation of the unlisted options:

Volatility (%)	133%
Risk free interest rate (%)	4.35%
Expected life of option (years)	2
Exercise price per terms and conditions	$0.19
Underlying security price at grant date	$0.14
Expiry date	15 July 2028
Value per option	$0.082

During the period 1,272,099 zero exercise price options (ZEPOs) were granted to Employees. The unlisted options were issued on 15 July 2026 at a zero-exercise price, expiring on 15 July 2031. These options vested 100% on the grant date. The underlying value of the options was determined to be $0.14 per option, based on the Company's share price at the grant date.

During the period 687,772 zero exercise price options (ZEPOs) were granted to CEO and 2,142,857 zero exercise price options (ZEPOs) were granted to Directors. The unlisted options were issued on 09 September 2026 at a zero-exercise price, expiring on 09 September 2031. These options vest 1/4 each year starting on grant date until the 3rd anniversary of the grant date. The underlying value of the options was determined to be $0.14 per option, based on the Company's share price at the grant date.

Note 11. Dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Note 12. Earnings per share

	30 September 2026 $	30 September 2025 $
Loss after income tax attributable to the owners of Amplia Therapeutics Limited	(4,625,320)	(4,176,563)

	30 September 2026 Number	30 September 2025 Number
Weighted average number of ordinary shares used in calculating basic earnings per share	513,256,844	426,457,520
Weighted average number of ordinary shares used in calculating diluted earnings per share	513,256,844	426,457,520

Note 12. Earnings per share (continued)

	Cents	Cents
Basic and diluted earnings per share	(0.90)	(0.98)

Note 13. Commitments and contingencies

Licenses (AMP945 & AMP886)

Under the in-licence agreement with Cancer Research Technology Limited ("CRT") signed in March 2018, the Company was required to use commercially reasonable efforts to develop AMP945 by filing an Investigational New Drug ("IND") application or commence a Phase 1 trial within two years. This obligation was met in October 2020 when the Company initiated a Phase 1 trial of AMP945.

For AMP886, the Company agreed to file an IND or commence a Phase 1 trial within three years. In November 2021, CRT agreed to extend the deadline for filing an IND or commencing a Phase 1 trial of AMP886 until 31 December 2023. Under the license agreement there is an annual maintenance fee of between US$15,000 and US$20,000 per annum. Additionally, under this agreement there are various milestone payments. Under the license agreement US$50,000 is payable for the commencement of any further Phase 1 clinical trial and US$50,000 for the allowance of any further INDs, noting that two IND's have been awarded to the Company and as a result US$150,000 has been paid to CRT.

Upon commencement of the first Phase 2 trial (as defined in the in-license agreement) of either AMP886 or AMP945, a milestone payment of US$250,000 is due to CRT. Further milestone payments would only become due and payable upon commencing additional Phase 2 and 3 studies, regulatory approvals and ultimately commercialisation. No amounts for these have been accrued.

Intellectual Property Royalties on the Use of MIS416 – Vendors

The Company must pay to the original Vendors 3.25% of net revenues on any product sales and licence revenues arising from the use of MIS416 to treat radiation injury, as described in a number of granted patents and patent applications having a priority date in 2009, expiring at the end of the respective patent periods.

Collaborations

The Group has entered a collaborative arrangement with the Garvan Institute of Medical Research (Garvan) for work being done to develop FAK inhibitor AMP945 in combination with gemcitabine and nab-paclitaxel. Upon first dosing of a patient in an Amplia-sponsored clinical trial in pancreatic cancer a milestone payment of AU$100,000 was paid to Garvan. Further milestone payments would only become due and payable upon commencing additional Phase 1/2 (A$100,000, maximum of one more payment) and Pivotal Phase 3 (A$150,000, maximum of two payments) studies, regulatory approvals and ultimately commercialisation. Milestone payments for regulator approval of certain expedited development programs will also be paid if and when these are achieved.

The Company entered into a Funding and Collaboration Agreement with the Australia New Zealand Gynaecological Oncology Group ("ANZGOG") in May 2026 for the conduct of the PRROSE Phase 1/2 clinical trial of Narmafotinib. Under the agreement, the Company has committed total funding of $2.2 million**,** payable in instalments upon achievement of specified clinical and research milestones through to December 2030. The Company is also required to provide the study drug required for the trial at no cost to ANZGOG. As at 30 September 2026, $892,000 has been incurred under the agreement, with the remaining funding commitment payable subject to achievement of the relevant milestones.

Research and development

The Group has entered into an agreement with IQVIA related to research and development activities for the Phase 2 ACCENT clinical trial using AMP945 with gemcitabine and Abraxane, the total estimated value of the agreement is $3.97 million, for the professional fees spanning through to 2026. When certain milestones in the trial are satisfied, the Group will need to settle advanced payments. At balance date, $3.22 million of the agreement has been incurred. As part of the agreement the Group is also expecting to incur ongoing pass-through costs and investigator fees in relation to the trial, also spanning through to 2026.

Note 13. Commitments and contingencies (continued)

Additionally, in July 2025 the Group entered into a separate agreement with IQVIA for the provision of research and development services in relation to the Phase 2 AMPLICITY clinical trial of AMP945. The total estimated value of the agreement is $3.89 million. As at balance date, $1.17 million of the agreement has been incurred. The Group announced a temporary halt to patient recruitment on 7 April 2026 following protocol-defined safety events. Accordingly, the remaining commitment under this agreement is subject to revision, with management currently negotiating amendments to the payment schedule.

Note 14. Events after the reporting period

On 22 October 2026, the Company received an R&D Tax Incentive refund of $4,778,235 for the financial year ended 31 March 2026.

No other matter or circumstance has arisen since 30 September 2026 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

Amplia Therapeutics Limited
Directors' declaration
30 September 2026

In the Directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;

- the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 September 2026 and of its performance for the financial half-year ended on that date; and

- there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of Directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the Directors



Jane Bell
Non-Executive Chair

27 November 2026

Grant Thornton Audit Pty Ltd
Level 22 Tower 5
Collins Square
727 Collins Street
Melbourne VIC 3008
GPO Box 4736
Melbourne VIC 3001

T +61 3 8320 2222

Independent Auditor's Review Report

To the Members of Amplia Therapeutics Limited

Report on the half-year financial report

Conclusion

We have reviewed the accompanying half-year financial report of Amplia Therapeutics Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 September 2026, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half year ended on that date, including material accounting policy information, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Amplia Therapeutics Limited does not comply with the *Corporations Act 2001* including:

a giving a true and fair view of the Group's financial position as at 30 September 2026 and of its performance for the half year ended on that date; and

b complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES *110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

© 2026 Grant Thornton Audit Pty Ltd. as trustee for the Grant Thornton Audit Unit Trust

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Audit Pty Ltd as trustee for the Grant Thornton Audit Unit Trust is a member firm of Grant Thornton International Ltd (GTIL) and is part of the Grant Thornton Advisors (GTA) multinational platform (being a group of firms within the GTIL network that connects priority markets and operates with aligned standards, technology and delivery expectations). GTIL, GTIL member firms, and the GTA platform firms are separate legal entities, are not a worldwide partnership, are not agents of and do not obligate one another, and are not liable for one another's acts or omissions. Services are delivered by the member firms; GTIL does not provide services to clients. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Audit Pty Ltd as trustee for the Grant Thornton Audit Unit Trust and its related entities. Liability limited by a scheme approved under Professional Standards Legislation.

Material uncertainty related to going concern

We draw attention to Note 3 in the financial report, which indicates that the Group incurred a net loss of $4,625,320 and net cash used in operating activities of $7,000,267 during the half year ended 30 September 2026. As stated in Note 3, these events or conditions, along with other matters as set forth in Note 3, indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our conclusion is not modified in respect of this matter.

Directors' responsibility for the half-year financial report

The Directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 30 September 2026 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Grant Thornton

Grant Thornton Audit Pty Ltd
Chartered Accountants

J Vasilou

J D Vasilou
Partner – Audit & Assurance

Melbourne, 27 November 2026

© 2026 Grant Thornton Audit Pty Ltd. as trustee for the Grant Thornton Audit Unit Trust – All rights reserved.